Search

Displaying results 2121 - 2130 of 9667 in total
  1. Drug

    Technetium Tc-99m pertechnetate

    go.drugbank.com/drugs/DB09314
    ApprovedInvestigational

    Pertechnetate has a wide variety of uses within nuclear medicine as it distributes within the body to a similar extent as iodine. … Technetium-99m's short half life (6 hours) makes storage impossible, therefore it is supplied as its parent nuclide molybdenum-99, which spontaneously decays to technetium-99 through beta decay.

  2. Drug

    Myrrh

    go.drugbank.com/drugs/DB11605
    ApprovedInvestigational

    Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora

  3. Drug

    Cefiderocol

    go.drugbank.com/drugs/DB14879
    ApprovedInvestigational

    [A189057] It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase … [L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.

  4. Drug

    Polycarbophil

    go.drugbank.com/drugs/DB09311
    ApprovedWithdrawn

    Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali.

  5. Drug

    Gallium citrate Ga-67

    go.drugbank.com/drugs/DB06784
    Approved

    Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metasta...

  6. Drug

    Benzphetamine

    go.drugbank.com/drugs/DB00865
    ApprovedIllicit

    It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)

  7. Drug

    Bezlotoxumab

    go.drugbank.com/drugs/DB13140
    Approved

    [A260106] The drug was granted full approval by the EMA on January 18, 2017.[L47191]

  8. Drug

    Pegaspargase

    go.drugbank.com/drugs/DB00059
    ApprovedInvestigational

    [A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic … The pegylation of pegaspargase allows access to the enzyme's active sites while limiting reticuloendothelial system uptake and reducing immune detection, and it also increases the half-life of L-asparaginase

  9. Drug

    Alglucerase

    go.drugbank.com/drugs/DB00088
    ApprovedWithdrawn

    Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market. … The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues.

  10. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … [L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies